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Background: Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in reproductive-age
women. It is one of the risk factors of metabolic syndrome (MetS). These two syndromes have an inflammatory
etiologic foundation along with oxidative stress. The present study aimed to compare the dietary intake of
antioxidant micronutrients in PCOS women with and without MetS.
Materials and methods: Overall, 42 participants eligible for this nested case control study were selected by the
convenience sampling method. The case group included 14 PCOS patients with MetS and the control group
included 28 PCOS patients without MetS. The dietary intake assessment of selenium, chromium, zinc, carotenoids,
vitamin D and vitamin E was carried out by a 147-item Food Frequency Questionnaire (FFQ). PCOS and MetS were
diagnosed using the Rotterdam criteria and NCEP ATP III, respectively. Statistical analysis was performed using
SPSS16 software, T-test and Mann Whitney. Significant P-value was considered 0.05.
Results: Dietary intake of antioxidant micronutrients (selenium, zinc, chromium, carotenoids and vitamin E) was
significantly lower in the PCOS women with MetS than in the control group (P < 0.05).
Conclusion: Since the PCOS patients without MetS had more intake of the aforementioned micronutrients than
those with MetS, it is assumed that the dietary intake of these nutrients could probably have a protective effect on
MetS.
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Polycystic ovarian syndrome (PCOS), as the most com-
mon endocrine disorder in women of reproductive age,
has engaged about 5–10% of women throughout the
world [1]. In addition to irregular menstrual cycles,
chronic anovulation and hyperandrogenism, numerous
metabolic complications are also seen in PCOS-afflicted
women such as obesity, hyperlipidemia, hyperinsuline-
mia, insulin resistance (IR), dysglycemia, and increased
risk of cardiac diseases and endometrial cancer [1]. If
PCOS is left untreated in the long term, the syndrome
may lead to chronic risks which the metabolic syndrome
(MetS) can be mentioned [1].
MetS is a complex disorder characterized by a com-
bination of several metabolic risk factors together with a
series of symptoms, including abdominal obesity, dyslip-
idemia, hypertension, IR (with or without glucose toler-
ance), pre-inflammatory condition and hypercoagulable
state [2]. Since this syndrome can cause cardiovascular
diseases (CVDs) and diabetes, studying its root causes
and preventions is of crucial importance. Due to differ-
ences in the diagnostic indicators, race and geographical
features, MetS prevalence differs among the women suf-
fering from PCOS throughout the world ranging from 7
to 43% [3, 4]. IR is one of the basics of PCOS and MetS
pathophysiology [1].
IR is induced due to the oxidative stress-related mech-
anisms [5]. Diet has been recognized as one of the modi-
fiable factors of the lifestyle with a significant impact on
oxidative stress and IR [6]. Improper diet and sedentary
lifestyle can undoubtedly cause and intensify the PCOS
symptoms by aggravation of IR and serum insulin level
along with increasing obesity [7]. Previous studies have
addressed the role of some micronutrients in IR and its
improvement [8].
Selenium (Se) is one of the essential minerals with
antioxidant properties, which acts against the free oxy-
gen radicals in reactive oxygen species (ROS) signaling
pathways [9]. The inverse relation of Se and other anti-
oxidants’ consumption with lower serum level of C-
reactive protein (CRP) among the women suggests the
anti-inflammatory role of this antioxidant nutrient.
Moreover, high Se consumption can decline the risk of
oxidative stress and inflammation-induced diseases
through making changes in lipid metabolism [10].
The decreased serum level of Se was observed in
PCOS patients [10]. Some studies have shown improve-
ments in the insulin metabolism parameters and even
triglyceride (TG) and very low-density lipoprotein
(VLDL) level upon Se supplement prescription [11].
Other studies have reported a negative correlation be-
tween the dietary Se intake and salicylic acid (marker of
inflammation) level and MetS [12]. However, Zagrodzki
et al. found no significant difference in the Se serumlevel among PCOS patients and healthy subjects [13].
Hosseinzadeh et al. reported no desirable results from
administration of Se supplement in PCOS patients. They
declared that Se can even deteriorate the IR condition in
these patients [14]. Surprisingly, Obeid et al. have men-
tioned a positive relationship between the Se content of
the blood and MetS components [15].
Carotenoids are another class of micronutrients whose
role in the improvement of oxidative stress has been well
documented [16]. Ni et al. have shown the improving ef-
fect of carotenoids on IR [8]. Chromium (Cr) is a micro-
nutrient, which can intensify the insulin effect. Hence, it
is an essential element for glucose and lipid metabolism
[17]. Cr supplements are reportedly able to improve in-
sulin sensitivity and MetS parameters in type 2 diabetic
patients [18]. Cr supplementation can have useful im-
pacts on glycemic control and improvement of CVD risk
and oxidative stress state in PCOS patients [19].
Zinc (Zn) is known as one of the basic components of
superoxide dismutase enzyme and a cofactor for antioxi-
dative enzymes [20]. This important element has a signifi-
cant role in reducing IR and inflammatory markers [21].
The genes related to the regulation of vitamin D level
have been proven to be involved in both lipid and glu-
cose metabolism and blood pressure control [22].
Through preventing DNA damage at the cellular level,
vitamin D may inhibit the inflammatory and oxidative
stress processes [23]. Some studies have suggested the
relationship between vitamin D and obesity, IR and
hypertension among PCOS women [24, 25]. Vitamin D
supplementation in PCOS women can also decrease the
total testosterone (TT) and factors related to inflamma-
tion and oxidative stress and improve the IR and meta-
bolic profiles [26]. Moreover, an inverse relationship has
been observed between serum vitamin D and MetS com-
ponents, including abdominal obesity, hypertension, and
abnormal glucose homeostasis [27].
Antioxidant effects of vitamin E have been also proven
[28]. The nutritional intake of this vitamin was lower in
PCOS women in comparison with healthy subjects [29].
However, there are some controversies on the relation of
this vitamin with MetS [30, 31].
To the best of knowledge, no study has addressed so
far the nutritional intake of the above-mentioned micro-
nutrients in PCOS patients with and without MetS, the
present study aimed to investigate and compare their
nutritional intake in these two mentioned groups of
women.
Methods
The present case-control study, which was accomplished
from October 2016 to September 2017 in Tehran (Iran)
on 42 PCOS patients, was approved by the Ethical Com-
mittee of Tarbiat Modares University (D525503). Indeed,
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study [32].
Among the PCOS patients who were investigated in
the primary full study, 14 PCOS subjects with MetS
were detected and considered as the case group. Also 28
randomly selected patients (twice the number of case
group) who had PCOS but not MetS were considered as
the control group. Since, we did not have more than 14
PCOS patients with MetS, for increasing the efficiency
of the comparison, enhancement of the study accuracy,
and decrease in the study errors statistically, we used a
2-fold control (28 PCOS patients without MetS). The
two groups were matched in terms of age, BMI, physical
activities, economic condition, and education level. The
convenience sampling method was employed. The sub-
jects were selected among the PCOS patients who re-
ferred to the gynecology or endocrine departments of
the hospitals and private offices and met the inclusion
criteria. All women were informed about the project and
the written informed consent was obtained from all of
them before participating in the study.
The inclusion criteria were Iranian race, diagnosis of
PCOS, age range of 18–40 years, no medication with in-
fluence on MetS and PCOS components and appetite,
no specific diet, and no pregnancy. The case group
members should also have MetS in addition to the men-
tioned criteria. The Rotterdam criteria were used to ver-
ify the PCOS diagnosis (after the rejection of other
androgen-increasing disorders). If two out of the follow-
ing three observations were present, the participants
were labeled as having PCOS:
– H [clinical (hirsutism) and/or biochemical
hyperandrogenism (increased serum TT and/or free
androgen index (FAI)]
– O [ovulation dysfunction (amenorrhea or
oligomenorrhea)]
– P [PCOS sonographic view on ultrasound] [1].
MetS diagnosis was based on the NCEP ATP III cri-
teria at the presence of the following three or more
items [3]: waist circumference (WC) at least 95 cm in
Iranian women [33], TG level of ≥150 mg/dl, high-
density lipoprotein (HDL) < 50mg/dl, blood pressure
(BP) ≥130/85 mm-Hg, and fasting blood sugar (FBS) ≥
110 mg/dl.
We asked the patients about their total revenues and
then subtracted the expenditures incurred. These data
were considered as economic levels after dividing by
three for making tertiles. Thereafter, we assumed tertile
1 as level one, and so on. Eventually, economic level of
the participants was classified into tertiles as follows:
First level (low economic status), second level (medium
economic status) and third level (high economic status).Physical activity of the participants was classified into
the following three levels based upon the weekly sched-
ule for exercise for at least 20 min per week: level 1
(none), level 2 (1–2 times/week), and level 3 (≥3 times/
week).
A 147-item food frequency questionnaire (FFQ) was
filled out for all participants. The reliability and validity
of the questionnaire had been confirmed previously [34].
The questionnaire assesses the habitual diet over the
past year. Participants were asked about their intake fre-
quency for each food item consumed during the past
year on a daily, weekly, or monthly basis; portion sizes
of consumed foods reported in household measures
were then converted to grams. In order to analyze food
items in terms of the energy and micronutrient intake,
designed Excel worksheet according to “Nutritionist 4
software data” (Iranian Food Composition Table and the
food composition tables (FCT) of the United States De-
partment of Agriculture (USDA)) was used. Energy in-
take of subjects was adjusted and then Z-score of the
energy-adjusted intakes was computed. After that we re-
moved out of range data in terms of energy (removed ±
4SD of energy intake data). These dietary data allowed
the calculation of the total intake per day. Using the ob-
tained data, the amount of micronutrient intake (carot-
enoids, Zn, Se, Cr, vitamin D, and vitamin E) was
determined for each participant.
Moreover, blood pressure and anthropometric mea-
surements (height, weight, BMI and WC), hirsutism (as
a clinical sign of hyperandrogenism) and menstrual re-
gularity evaluations, ovarian ultrasonography and serum
hormonal and metabolic parameter assays (to determine
the amount of serum androgenic parameters and serum
components of MetS) were performed.
Clinical and laboratory evaluations
Hyperandrogenism, the fundamental yardstick in the
diagnostic process of PCOS, appears as clinical demon-
stration and/or biochemical hyperandrogenemia. The
Ferriman-gallwey score (FG- score) of 8 or more was de-
fined as hirsutism (clinical hyperandrogenism) [32].
Hyperandrogenemia is characterized by an unusually
high level of androgen produced by the ovaries or the
adrenal glands [35]. Hyperandrogenemia was defined ac-
cording to the cut-off determined for Iranian women
[36]. TT and FAI were considered as diagnostic parame-
ters for hyperandrogenemia. None of the participants
had taken a medication interfering with their hormonal
and metabolic profile in the last 3 months prior to the
study.
TT and Sex Hormone Binding Globulin (SHBG) were
measured by electro chemo-luminescence using Roche
Company kit (Germany) and Kobas E 411 device
(Germany). FAI was determined by dividing TT (nmol/
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FBS were assessed by enzymatic-colorimetric method,
and HDL was tested by immunoinhibition assay using
Pars Company kits (Iran) and auto-analyzer device
(BT2000) (Italy).
Ovarian volume larger than 10 cm3 in at least one ovary or
observation of more than 5–8 small follicles was considered
as positive PCOS. Menstrual cycle duration more than 35
days (oligomenorrhea) or more than 3months (amenorrhea)
was considered as positive ovulation dysfunction.
The minimum correlation coefficient, study power,
and confidence interval were 0.5, 80 and 95%, respect-
ively in the primary study. After data collection, they
were analyzed by SPSS 16 software. Two-independent-
samples T-test and Chi2 test were employed to compare
the matching of the case and control groups. The
Kolmogorov-Smirnoff’s (KS) test was used to check the
normality of quantitative variables. In order to investi-
gate the difference between the two groups, T-test and
Mann-Whitney U test were performed for the normal
and non-normal variables, respectively. P < 0.05 was con-
sidered significant.
Results
According to Table 1, the two groups were not signifi-
cantly different in terms of age, BMI, education level,
economic level and physical activity (P > 0.05).
Table 2 presents the results of the comparison be-
tween the case and control groups in terms of PCOS
diagnostic criteria, MetS components and IR indicators.Table 1 Comparison of demographic components between the cas
Demographic components PCOS with MetS
n = 14
Age (year) 31.28 ± 4.87
BMI (Kg/m2) 29.92 ± 3.71
Physical activity
No physical activity 9 (33.3)
1–2 times a week 3 (60)
> 3 times a week 2 (20)
Education level
High school and diploma 3 (21.4)
Bachelor and technician 8 (57.1)
Higher than bachelor 3 (21.4)
Economic condition
Low economic status 5 (35.7)
Medium economic status 4 (28.6)
High economic status 5 (35.7)
PCOS Polycystic Ovary Syndrome, MetS Metabolic Syndrome, BMI Body Mass Index
*P-values related to t-Test
** P-values related to Chi-square test
Data are given as N (%) except for age and BMI (Mean ± SD)
Statistical significance was set at P < 0·05As shown, the FG-score of hirsutism was significantly
higher in the case group (P = 0.01). TT and FAI were
significantly higher in the case group comparing to the
control group (P < 0.001 and P = 0.005, respectively).
Among the MetS components, HDL, TG, systolic blood
pressure (SBP), and diastolic blood pressure (DBP)
showed a significant difference between the two groups.
HDL was significantly lower (P = 0.001), and TG (P <
0.001), SBP (P = 0.002) and DBP (P = 0.011) were signifi-
cantly higher in the case group than in the control
group. FBS and WC of the two groups, however, showed
no significant difference (P > 0.05). Fasting insulin and
the homeostatic model assessment of insulin resistance
index (HOMA-IR) were significantly higher in the case
group comparing to the control group, indicating the
higher IR among the case group members (P = 0.041 and
P = 0.027, respectively). The quantitative insulin sensitiv-
ity check index (QUICKI) was significantly lower in the
case group, reflecting the lower insulin sensitivity in
these participants (P = 0.025).
Results in Table 3 show that the dietary intake of Se
(P < 0.001), Cr (P = 0.006), Zn (P = 0.038), carotenoids
(P < 0.001), and vitamin E (P < 0.001) was significantly
lower in the case group comparing to the control group.
However, the dietary intake of vitamin D showed no sig-
nificant difference between the two groups (P > 0.05).
Discussion
The results of the present study indicate that the nutri-
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Table 2 Comparison of basic PCOS, MetS and insulin resistance diagnostic criteria between the case and control groups





Hirsutism score (FG-Score) 9.14 ± 3.65 5.53 ± 4.25 0.01*
Number of ovarian follicle 10.64 ± 4.03 12.25 ± 3.06 0.25*
Menstruation duration (day) 56.57 ± 31.4 52.53 ± 29.26 0.72*
TT (nmol/l) 3.42 ± 3.02 1.09 ± 0.61 < 0.001**
FAI 9.91 ± 9.57 3.85 ± 3.53 0.005**
SHBG (nmol/l) 37.67 ± 13.47 39.88 ± 19.60 0.70**
Metabolic syndrome components
FBS (mg/dl) 92.21 ± 8.45 91.46 ± 9.04 0.10**
HDL-C (mg/dl) 39.35 ± 9.73 49.6 ± 8.90 0.001**
TG (mg/dl) 192.21 ± 51.20 108.36 ± 44.88 < 0.001**
WC (cm) 95.92 ± 10.99 92.12 ± 11.14 0.30**
SBP (mmHg) 128.86 ± 25.74 110.68 ± 10.74 0.002**
DBP (mmHg) 82.57 ± 24.46 70.25 ± 11.12 0.01*
Insulin resistance indices
Fasting insulin (μU/ml) 22.71 ± 17.49 14.45 ± 8.0 0.04**
HOMA-IR 5.25 ± 3.68 3.28 ± 1.90 0.02 **
QUICKI 0.30 ± 0.02 0.32 ± 0.02 0.02**
PCOS Polycystic Ovary Syndrome, MetS Metabolic Syndrome, FG-Score Ferriman-Gallwey score, TT Total Testosterone, FAI Free Androgen Index, SHBG Sex Hormone
Binding Globulin, FBS Fasting Blood Sugar, HDL-C High Density Lipoprotein Cholesterol, TG Triglyceride, WC Waist Circumference, SBP Systolic Blood Pressure, DBP
Diastolic Blood Pressure, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, QUICKI Quantitative Insulin Sensitivity Check Index
Data are presented as mean ± SD. *P-values refer to Mann-Whitney test. **P-values refer to t-Test. P < 0.05 was considered significant
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compared with those without MetS (control group). The
IR in the case group was significantly higher than in the
control group.
IR is the fundamental etiology of PCOS [1]. It is also a
key factor in the pathophysiology of MetS whose effect
on this syndrome has been proven [38]. The presence of
some changes in the IR specific indicators, which illus-
trates increased IR in the case group, can be justified
due to the severity of the metabolic complications of
these patients comparing to the non-MetS patients.Table 3 Comparison of the nutritional intake of the
micronutrients between the case and control groups





Se (μg/day) 37.52 ± 28.15 110.42 ± 49.93 < 0.001
Cr (μg/day) 0.03 ± 0.08 0.11 ± 0.08 0.006
Zn (mg/day) 6.76 ± 6.43 10.46 ± 4.60 0.03
Carotenoid (mg/day) 2.01 ± 8.66 15.78 ± 9.80 < 0.001
Vitamin D (μg/day) 2.58 ± 1.57 3.13 ± 1.40 0.25
Vitamin E (mg/day) 6.17 ± 7.20 17.21 ± 7.02 < 0.001
PCOS Polycystic Ovary Syndrome, MetS Metabolic Syndrome, Se Selenium, Cr
Chromium, Zn Zinc
Data are reported as mean ± SD
P-value related to t-Test
P < 0.05 was considered significantOxidative stress can result in IR through various mo-
lecular mechanisms [5]. Se is one of the essential antiox-
idants, which can protect the cells against oxidative
stress by expression of selenoprotein genes and anti-
inflammatory mechanism [39]. According to the litera-
ture review, no similar study has been conducted on
comparing the dietary intake of micronutrients in PCOS
patients with and without MetS. Therefore, we inevitably
used the studies, which had investigated these micronu-
trients separately.
Reduction in the serum level of Se was observed in
PCOS patients [10]. In a systematic review in 2019 in
Iran, the decreased serum level of Se was found in PCOS
patients. Only one-fourth of the reviewed papers re-
ported the protective impact of Se supplement on IR;
Two third of them, however, proved the antioxidant ef-
fect of Se. In the above study, the papers addressing the
anti-androgenic effects of Se showed contradicting re-
sults. It was also indicated that Se can reduce dyslipid-
emia and IR. The authors eventually declared that the
available data are not sufficient to support the protective
effect of Se in PCOS patients [40]. Gregorio et al.
expressed that application of antioxidants, especially via
nutrition, can improve MetS, and that lifestyle change
can be an effective approach in the treatment of these
patients [41]. Some studies considered Se supplement
administration as an effective method in MetS patients
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tween Se nutritional intake and serum level of salicylic
acid as an inflammatory marker of MetS components,
found out lower salicylic acid levels in women receiving
more nutritional Se. They believed that nutritional Se
has anti-inflammatory potential, which can be effective
in MetS patients [12]. In contrary, some studies have re-
ported the impact of increased serum level of Se on
MetS enhancement [43]. Ford et al. conducted a cross-
sectional study in 2003 in the US and evaluated the anti-
oxidant conditions among MetS patients. The results in-
dicated that adult MetS patients had lower
concentrations of several antioxidants, which can justify
the increased risk of diabetes and CVDs among them;
however, they showed no significant difference in the
serum Se level [44]. Ghayour-Mobarhan et al. (2008)
studied the obese MetS women in UK and realized that
their serum Se level and nutritional intake of Se were
higher than those in healthy women [45].
The contradiction in the results of various studies in
terms of Se relationship with MetS could be due to di-
verse study design, difference in the studied population,
racial diversity, and fundamentally, the complex nature
of both MetS and PCOS. Moreover, the design of the
present study is different from that of the mentioned re-
searches, and the studied population was selected from
among PCOS patients and not healthy women, which
can be effective on the difference in the results. Further-
more, we investigated the dietary intake of the men-
tioned micronutrients, not their serum level. Since the
majority of the previous studies have addressed the
serum level rather than the dietary intake, we inevitably
compared our results with these studies.
The current research results also indicated that the
dietary intake of Cr was lower in the PCOS patients with
MetS when compared with those without MetS. Simi-
larly, another research showed that 8 weeks of Cr appli-
cation in infertile women with PCOS could have a
positive impact on glycemic control, decline of fasting
insulin, HOMA-IR, TG, VLDL and total cholesterol, in-
crease of antioxidant capacity, and improvement of oxi-
dative stress [19]. A review article stated that Cr
supplement has limited impact on the weight loss, glu-
cose control, lipid profile and hormonal disturbance of
PCOS women [46]. Cr has a high antioxidant potential
[47]. Due to the insulin-mimetic effects of Cr and Se,
these two elements have been prescribed to improve
MetS [42]. Regarding the etiologic background of oxida-
tive stress in MetS [48] and PCOS, dietary deficiency of
this antioxidant micronutrient (Cr) in people suffering
from both MetS and PCOS seems rational in compari-
son with those only having PCOS. Hence, low dietary in-
take of Cr could be related to the deterioration of their
metabolic and hormonal condition.In a meta-analysis conducted by Abedini et al. in 2019,
it was revealed that the serum level of Zn is lower in
women with PCOS when compared to the control group
[49]. In conformity with the present study, Freitas et al.
observed lower nutritional intake of Zn in people with
MetS when compared with healthy subjects [50]. In con-
trary, Fang and colleagues observed no relationship be-
tween the serum level of Zn and MetS and its
components [43]. In the present study, it was revealed
that the dietary intake of Zn was lower in the PCOS pa-
tients with MetS. Therefore, if it cannot be considered
as one of the definite involving factors in MetS develop-
ment in PCOS patients, it can be probably effective in
deterioration of the metabolic condition of these pa-
tients. This can be due to the antioxidant function of Zn
and the related epigenetic modulations. The study of
Fang et al. was performed on Chinese men and women
over 40 years old while the present study was performed
on women with PCOS. The effect of Zn on the insulin
signaling mechanisms has been proven [51]. Studies
have revealed that IR in PCOS patients is the conse-
quence of a post-receptor defect in insulin performance
[52]. Regarding the etiologic basis of IR in these patients
and considering the role of Zn in insulin signaling mech-
anisms, the difference between the results of this study
with that of Fang et al. could be justified by the fact that
in PCOS patients, the effect of Zn and its dietary intake
on the metabolic status and components of MetS, which
is also linked to insulin resistance, is more pronounced.
Studies have suggested the improving effect of some
carotenoids on IR [8]. Researchers have related the lower
serum level of some carotenoids with insulin sensitivity
deficit and declared that long-term deficiency of beta-
carotene can predict type 2 diabetes [53]. Some other ca-
rotenoids can decline the cardio-metabolic risk factors
and visceral fat via modulating the expression of nuclear
transcription factors such as NF-kB [54]. Other studies
have mentioned the importance of lipid-soluble caroten-
oids in MetS improvement due to their antioxidant and
anti-inflammatory effects [55]. In 2019, it was shown
that carotenoids are inversely related to MetS [56]. Mei
et al., however, observed no relation between the dietary
intake of carotenoids and MetS in 2015 [31]. In 2018, a
study showed that crocetin carotenoid can decrease the
PCOS induced by dihydrotestosterone in rats [57]. In
the present study, the dietary intake of carotenoids was
significantly lower in the PCOS patients with MetS when
compared to the control group. Due to the antioxidant
and anti-inflammatory potential of carotenoids, dietary
intake deficiency of these micronutrients can be effective
in the worsening of the metabolic condition of PCOS
patients.
Low vitamin E intake was observed in PCOS patients
[29]. Administration of dietary supplement of vitamin E
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tients [58–60]. Wei et al. observed no relationship be-
tween the nutritional intake of vitamin E and MetS [31].
However, Kim et al. declared the protective effect of
vitamin E provided by food on MetS, which can be due
to the antioxidant property of this vitamin [30]. Low nu-
tritional intake of alpha-tocopherol (a type of antioxidant
vitamin E) has been related to IR [53]. Goncalves et al.
(2017) also observed the effectiveness of vitamin E in
prevention from MetS [54].
In this study, the shortage of dietary intake of vitamin
E was observed in the PCOS patients with MetS. The
difference between our study and that of Wei et al. could
be due to race and population study differences, as well
as the different design of these two studies. Wei et al.
studied men and women over 18 years old while the sub-
jects of this study suffered from an insulin-resistance
disease (PCOS), and in the case group, this was exacer-
bated by the presence of MetS. Therefore, lower levels
of carotenoid and vitamin E in the diet of PCOS patients
(comparing to healthy subjects in terms of IR) could be
more effective in the emergence of MetS and deterior-
ation of their metabolic condition.
The present study enjoys some valuable strengths. It is
the first research that compares the dietary intake of
micronutrients in PCOS patients with and without
MetS. Elimination of confounding factors via matching
the two groups, employing precise inclusion criteria, and
application of the reliable and valid 147-item FFQ are
among the other strong points of this study. This is,
however, a case-control study, and hence, it could not
accurately define the cause-effect relationship. Time-
consuming nature of the 147-item FFQ and difficulty in
remembering and estimating the dietary intake in the
last year can be mentioned as the limitations of the
present study. Nevertheless, we excluded the estimations
with standard deviation (SD) above and below than 4.
According to the literature review, since, no study has
addressed the nutritional condition of PCOS patients
with and without MetS; therefore, we had to select the
similar studies carried out on PCOS and MetS patients
separately to compare their finding with ours. It seems
that further cohort studies with higher population and
clinical trials are required for more definite results. This
study also did not investigate the serum level of the
studied micronutrients, which could be helpful for fur-
ther scientific richness of the present research.
Conclusion
Since the results of the present study showed that PCOS
patients without MetS had more intakes of aforemen-
tioned micronutrients than those with MetS, hence, it
can be concluded that the dietary intakes of these nutri-
ents could probably have protective effects on MetS.Abbreviations
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